Zepbound and Mounjaro Philadelphia
Zepbound and Mounjaro contain tirzepatide but have different FDA-labeled indications. W8MD uses the correct product and diagnosis rather than treating the brand names as interchangeable marketing terms.
W8MD Philadelphia explains the difference between Zepbound for obesity and Mounjaro for type 2 diabetes, with tirzepatide safety and cost guidance.
What patients should know
Zepbound is approved for chronic weight management in eligible patients and for moderate-to-severe obstructive sleep apnea in defined adults with obesity. Mounjaro is approved to improve glycemic control in adults with type 2 diabetes. Prescribing, coverage and prior authorization should match the clinical indication.
Clinical review
Zepbound obesity indication
Personalized option
Zepbound OSA indication
Safety and follow-up
Mounjaro type 2 diabetes indication
Coverage and cost
Tirzepatide contraindications and warnings
Nutrition and sleep
Insurance documentation by diagnosis
Long-term planning
Nutrition, muscle and side-effect support
Approval status and medication safety
FDA approval applies to a specific product, population, indication, dose and formulation. A medicine approved for type 2 diabetes is not automatically approved for obesity, even when the active ingredient is shared. Off-label prescribing can be medically appropriate but must be identified as off label. Compounded drugs are not FDA approved, and investigational products should be obtained only through legitimate clinical trials.
GLP-1–based treatment commonly causes nausea, vomiting, diarrhea, constipation, abdominal discomfort or reflux. Product-specific labeling may include warnings related to thyroid C-cell tumors, gallbladder disease, pancreatitis, kidney injury from dehydration, severe gastrointestinal disease, hypoglycemia with certain diabetes medicines and pregnancy. W8MD reviews the current prescribing information rather than applying one warning list to every medicine.
Affordable GLP-1 pathways
| Pathway | Starting price | Qualification |
|---|---|---|
| Semaglutide-based | From $29.99/week | With qualifying insured visits; self-pay pathways from $59.99/week. |
| Tirzepatide-based | From $45/week | With qualifying insured visits; self-pay pathways from $69.99/week. |
Eligibility, product, dose, pharmacy, supplies, visits, insurance and availability affect actual cost. Compounded drugs are not FDA approved or generic versions of approved brands. Request a complete written estimate.
How W8MD can help
W8MD physicians have more than 20 years of clinical experience and provide integrated medical weight loss, nutrition and sleep care. The first visit is completed in person at 1718 Welsh Road so treatment can reflect medical conditions, prior attempts, medications, insurance, cultural preferences, goals and cost.
Follow-up reviews response, adverse effects, appetite, protein and hydration, blood pressure, metabolic health, sleep, strength and maintenance. No medication or program guarantees an amount or rate of weight loss.
W8MD patient experiences
★★★★★ “Fantastic program. Truly a life changer.” D.M. reported losing 87 pounds in about 10 months and maintaining substantial weight loss for years.
★★★★★ “Dr. Tumpati takes his time with you to explain everything—very thorough.” — Carolann Z.
Published W8MD testimonials. Individual results vary and do not guarantee an amount or rate of weight loss. Read more patient experiences.
Related Philadelphia and W8MD resources
Philadelphia care
Medication guidance
Contact W8MD Philadelphia
Poly-Tech Sleep & W8MD Weight Loss
1718 Welsh Road, 2nd Floor, Suite C
Philadelphia, PA 19115
215-676-2334
Request information
Use this form for nonurgent appointment and service questions. Do not submit emergencies or highly sensitive medical information.